Computer applications for prediction of protein–protein interactions and rational drug design by Grosdidier, Solène et al.
© 2009 Grosdidier et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Advances and Applications in Bioinformatics and Chemistry 2009:2 101–123
Advances and Applications in Bioinformatics and Chemistry
101
r e v i e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
Computer applications for prediction  
of protein–protein interactions and rational  
drug design
Solène Grosdidier1 
Max Totrov2 
Juan Fernández-recio1
1Life Sciences Department, Barcelona 
Supercomputing Center, Barcelona, 
Spain; 2Molsoft LLC, La Jolla, CA, USA
Correspondence:  Juan Fernandez-recio 
Life Sciences Department, Barcelona 
Supercomputing Center, C/Jordi Girona 
29, 08034 Barcelona, Spain 
Tel +34 934137729 
Fax +34 934137721 
email juanf@bsc.es
Abstract: In recent years, protein–protein interactions are becoming the object of increasing 
attention in many different fields, such as structural biology, molecular biology, systems 
biology, and drug discovery. From a structural biology perspective, it would be desirable 
to integrate current efforts into the structural proteomics programs. Given that experimental 
determination of many protein–protein complex structures is highly challenging, and in 
the context of current high-performance computational capabilities, different computer 
tools are being developed to help in this task. Among them, computational docking aims 
to predict the structure of a protein–protein complex starting from the atomic coordinates 
of its individual components, and in recent years, a growing number of docking approaches 
are being reported with increased predictive capabilities. The improvement of speed and 
accuracy of these docking methods, together with the modeling of the interaction networks 
that regulate the most critical processes in a living organism, will be essential for computa-
tional proteomics. The ultimate goal is the rational design of drugs capable of specifically 
inhibiting or modifying protein–protein interactions of therapeutic significance. While 
rational design of protein–protein interaction inhibitors is at its very early stage, the first 
results are promising.
Keywords: protein–protein interactions, drug design, protein docking, structural prediction, 
virtual ligand screening, hot-spots
Introduction
Protein–protein interactions (PPI) are involved in most of the essential processes 
that occur in living organisms, such as cellular communication, immunological 
response, and gene expression control. A detailed energetic and structural knowledge 
of these interactions is necessary to understand the complex regulatory and meta-
bolic interaction networks that occur in living organisms, with the ultimate goal of 
designing drugs for blocking or modifying interactions of therapeutic interest. Thus, 
targeting PPI of therapeutic interest with small-molecule compounds is becoming 
the Holy Grail of drug discovery. A number of experimental and computational 
methods have been reported to contribute to all the stages of the drug discovery 
process targeting PPI. High-throughput experimental methods, such as coexpression 
analysis1 and the yeast two-hybrid test,2 may be used to establish an interaction, and 
random mutagenesis3 to locate the interaction surfaces. Finally, X-ray crystallogra-
phy and/or nuclear magnetic resonance (NMR) provide the most detailed structural 
information of the atomic interactions in a protein–protein complex. However, 
although the number of three-dimensional (3-D) protein structures deposited in Advances and Applications in Bioinformatics and Chemistry 2009:2 102
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the Protein Data Bank (PDB)4 is rapidly growing, only a 
small fraction of numerous protein–protein complexes, 
frequently transient, has been experimentally characterized 
so far. The increasing availability of high-performance 
computing has favored the development of computer tools 
that can help in this task.
Computational prediction of a protein–protein complex 
geometry from the 3-D coordinates of the individual pro-
teins involved has a relatively short history.5 Early docking 
methods used purely geometrical criteria to evaluate the 
resulting solutions, and considered the conformation of 
the molecule side-chains as fixed (rigid-body assumption). 
While this approach demonstrated the ability to rebuild a 
protein–protein complex from its already mutually adjusted 
subunits,6,7 it was not accurate enough to model the induced 
fit of the interacting surfaces upon binding, and therefore 
the prediction results were clearly poorer when using the 
uncomplexed subunits.8 In order to perform more realistic 
simulations, recently developed docking methods include 
interface explicit or implicit flexibility,9,10 and a more accu-
rate energy function.11 While a 100% reliable automated 
prediction of the association of two proteins is beyond 
the reach of current methods, advances in energy calcu-
lations and in global minimization algorithms, together 
with the increasing availability of computing power, may 
lead to useful predictions at a proteomic scale in the next 
few years.
The development of computational methods to model 
protein–protein docking, identify promising binding 
pockets, and predict protein-ligand association will facili-
tate the discovery of small molecules capable of inhibiting 
or modifying PPI, a major new challenge in drug design. 
We can envisage a general strategy for a multidisciplinary 
drug discovery process that targets PPI of therapeutic 
interest, involving four major stages (Figure 1). In the 
following sections each of these stages will be discussed in 
detail, with the emphasis on the computerized techniques 
(Table 1).
Identification of PPI  
of biomedical importance
A plethora of biochemical and genetic experiments, such as 
cross-linking, co-immunoprecipitation and co-fractionation 
by chromatography, among others, have been traditionally 
used to establish specific interactions between proteins. 
Biophysical assays have been also developed to experimen-
tally measure kinetic and thermodynamic binding constants 
between two given proteins.12–16 From all the experimental 
methods, the yeast two-hybrid assay2 and correlation of 
mRNA expression profiles17 have propelled large-scale 
detection of PPI.1,18,19
In recent years, with all the available information derived 
from the genome sequencing projects, several computa-
tional tools have been applied to find and recognize PPI 
from genome sequences at a proteomic level. Analysis of 
co-evolution of proteins20 and gene fusion events21,22 can be 
used to detect putative PPI. A well-known study described 
the use of combination of techniques (correlated evolution, 
correlated mRNA expression profiles, and domain fusion 
patterns) to find 93,750 pairwise links between 4,701 (76%) 
functionally related yeast proteins, from which 4,130 links 
(between 1,223 proteins) were of the ‘highest confidence’ 
(validated by direct experimental techniques or by two of 
the three prediction techniques).23 Other methods are based 
on interacting domains,24 interacting motifs,25 and a variety 
of criteria such as similarity of phylogenetic trees,26 protein 
interaction network topology,27 signature products28 or 
genome-wide coevolutionary networks.29 There are some 
good recent reviews that give a complete view of the currently 
available methods to identify PPI.30–33
Other computational approaches focus on mining the 
literature, the whole ‘googleome,’ for PPI. A system for auto-
matic detection of PPI extracted from scientific abstracts was 
able to rebuild key interactions of the Drosophila cell cycle 
control for 33 of the 91 protein names used in the bibliography 
screening.34 A similar system, based on a general-purpose 
information extraction engine, identified interactions between 
two proteins from Medline abstracts with an accuracy of 77% 
and a coverage of 58% of the total interactions.35 Another 
method used discriminating words to identify Medline 
abstracts that described protein interactions, with an accuracy 
of 77% and a coverage of ∼50% (or 100% of accuracy with a 
coverage of ∼30%).36 A new text-mining method (PIE: Protein 
Interaction information Extraction system) is available on the 
web to extract PPI from literature (http://pie.snu.ac.kr/). This 
tool, consisting on an article filter followed by a sentence filter, 
has been trained on the BioCreAtIvE II workshop dataset, 
enriched by other selected known-interactions. Using a 
10-fold cross validation and 0.5 probability cutoff, the method 
showed a precision of 87.4% for the article filter, and 92.1% 
for the sentence filter.37
All the experimental and computational data on exist-
ing PPI were soon organized in various public databases: 
YPD and WormPD – Yeast and Caenorhabditis elegans 
Proteome Databases;38 MIPS – Munich Information Center for 
Protein Sequences’39 DIP – Database of Interacting Proteins;40 Advances and Applications in Bioinformatics and Chemistry 2009:2 103
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BIND – Biomolecular Interaction Network Database;41 and 
private ones, such as PathCodeTM from GPC-Biotech (http://
www.gpc-biotech.com/). This facilitated large-scale studies that 
aimed to map the network of PPI of complete living organisms. 
The first described maps were those of the hepatitis C virus;42 
vaccinia virus;19 Saccharomyces cerevisiae;43–45 Caenorhabditis 
elegans;46 or Helicobacter pylori.47 Other organisms followed, 
at different levels of completeness.48–51 The field is rapidly 
growing, and there are currently many web tools and data 
collections that are publicly available online (http://www.imb-
jena.de/jcb/ppi/jcb_ppi_databases.html).
Target characterization: Structural 
information about the protein–
protein complex and drugability 
of the targeted PPI
Location of the interface
Mutational studies
Alanine-scanning mutagenesis3 combined with kinetic 
and thermodynamic measurements can be used to experi-
mentally locate and characterize residues involved in PPI. 
A comprehensive database of energetic data for different 
Clinical studies
– Pharmacokinetics and toxicology
– Clinical trials
– Synthetic chemistry
– Biological assay
Lead discovery and optimization
– Empirical discovery: natural ligands, phage-display, HTS
– Rational design: peptidomimetics, virtual screening
Interface characterization
– Alanine scanning mutagenesis
– X-ray, NMR
– Protein–protein docking simulations
Protein–protein interaction identification and validation
– Biochemical and genetic experiments (cross-linking; co-immuno-
   precipitation; yeast two-hybrid; co-expression profiles...)
– Genome analysis (co-evolution; gene fusion...)
– Biological validation
Figure 1 Flow-chart of the drug discovery process targeting protein–protein interactions.Advances and Applications in Bioinformatics and Chemistry 2009:2 104
Grosdidier et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
protein–protein complexes, determined by alanine mutations 
(ASEdb), has been compiled and made publicly available 
(http://www.asedb.org/).52 This database is actively updated 
and it is commonly used both by experimentalists and by 
computational benchmark studies.53
Computational prediction of protein–protein 
interfaces
Can protein–protein interfaces be predicted from the structures 
of their components, or, in other words, are there specific 
chemical and physical characteristics on a protein–protein 
interface that we could use to predict protein-binding sites 
on a protein surface? The question is far from being solved. 
Pioneer studies found that PPI sites have specific structural 
characteristics that differentiate them from other areas of the 
protein surface.54–60 However, when oligomeric proteins were 
excluded from the analysis, the results showed that chemical 
composition of protein–protein interfaces does not seem to 
differ greatly from the rest of the solvent-accessible surface.61–63 
Although chemical and physical complementarity between the 
interacting surfaces is essential for the recognition, it is difficult 
to find simple chemical or structural patterns on the surface of 
proteins that unequivocally define a protein recognition site.
Alternative strategies for prediction of protein–protein 
interaction sites have been recently developed (Zhou and Qin 
recently reviewed all the different approaches).64 Amongst 
them, methods based solely on sequence information have 
been reported. Receptor-binding domains were predicted by 
analyzing hydrophobicity distribution on protein sequences.65 
Predictions were 59%–80% correct, depending on the data-
base of protein interactions used. A neural network method 
that uses sequence profiles and solvent exposure of neigh-
boring residues has been reported.66 The method was trained 
on 615 pairs of nonhomologous protein–protein complexes 
(homodimers and heterodimers), and was tested on different 
sets of bound and unbound proteins. In the case of unbound 
proteins, 70% of the predicted residues were correctly located 
at the protein–protein interfaces. More recently, Ofran and 
Rost developed a machine learning-based method called ISI 
(Interaction Sites Identified from Sequence) to identify inter-
acting residues from protein sequences only. They combined 
predicted structural features with evolutionary information 
with no reference to the 3-D structure of the protein, and 
the strongest interface residue predictions reached 90% of 
accuracy in a cross experiment.67 Another method, based on 
a 3-D cluster analysis that evaluates residue conservation 
on a set of 35 protein families, can identify interfaces and 
functional residues.68
In addition to conservation, a combination of physical and 
empirical methods can give promising results for interface 
prediction, as in the Promate server (http://bioinfo.weizmann.
ac.il/promate/).69 Considering energy-based approaches, 
the optimal docking area (ODA), a method based on the 
hypothesis that desolvation must play a central role during 
protein–protein binding, identifies continuous surface patches 
with optimal docking desolvation. This approach has been 
validated on 66 unbound non homologue protein structures 
involved in nonobligate protein–protein heterocomplexes 
and the ODA predicted regions were correct in 80 % of the 
cases.70 The strategy has been applied to numerous cases of 
biological and therapeutic interest, with excellent predictive 
results.71–74
Structure determination  
of protein–protein complexes
Once a target protein–protein interaction has been established, 
it is desirable to obtain the most detailed structural informa-
tion at atomic resolution of the protein–protein complex by 
X-ray crystallography and/or NMR experimental techniques. 
During the last decades, a number of protein–protein com-
plex structures of therapeutic interest have been solved and 
deposited in the PDB.4 However, solving the 3-D structure 
Table 1 Computer approach to rational design of inhibitors/enhancers of protein–protein interactions
Target identification
1. establish protein–protein interaction Correlated mRNA expression profiles; correlated elution; domain fusion patterns; 
automated literature mining
Target characterization
2. Locate interface Surface analysis; hydrophobicity profiles; 3-D cluster analysis; residue conservation
3. Modeling protein–protein interaction Rigid-body docking; energy minimization; side-chain refinement; flexible docking
4. Finding putative small-molecule pockets Analysis of “hot-spots”; surface cavities
Lead discovery and optimization
5. Mimicking interface energy minimization; graphic modelling
6. Ligand docking Flexible ligand docking; grid or explicit receptor representations; MC minimizationAdvances and Applications in Bioinformatics and Chemistry 2009:2 105
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of a protein–protein complex is still a long and difficult task, 
and the number of available coordinates of protein heterodi-
mers is relatively small compared to the number of deposited 
individual protein structures. Therefore, there is a need for 
reliable computational tools that can predict protein–protein 
complex formation and help to theoretically analyze the 
phenomenon of association between proteins.
Protein–protein docking prediction
The so-called “protein docking” problem, that is the predic-
tion of a protein–protein complex using only the coordinates 
of its separate subunits, is one of the major challenges in 
structural biology. Apart from the intrinsic academic interest 
in characterizing the determinants of molecular recognition, 
the scientific community increasingly requires computational 
tools to model the physiological interactions in which a pro-
tein is involved, once its 3-D structure has been solved. Given 
that the number of available 3-D structures of individual 
structures is significantly increasing with the upcoming struc-
tural genomics projects,75,76 and considering that solving the 
structure of a protein–protein complex is often qualitatively 
more difficult than solving its individual subunits, one can 
easily deduce the importance of computational prediction of 
protein–protein complexes for the proteomics era. For that 
reason, during the last 20 years, a variety of computational 
algorithms for automatic protein–protein docking have been 
developed.5,77,78
Geometry-based protein–protein docking methods
The analysis of protein–protein complex structures at atomic 
resolution gave the first glimpse of the determinants of pro-
tein docking. From the analysis of several protein–protein 
complex structures, the most obvious observation was that 
protein surfaces of interacting proteins at binding sites were 
often highly complementary (Figure 2).79,80 For that reason, 
early protein–protein docking algorithms were based on 
purely geometric criteria, aiming to maximize the shape 
complementarity between the two interacting molecules.7,80,81 
Conformational search of the best fit was performed on the 
rigid-body (ie, fixed backbone and side-chain conformation) 
representation of molecules, by geometric methods such as 
‘sphere-matching’ in the original DOCK algorithm.7
Many of the recently developed docking methods are 
still mainly based on the shape complementarity criterion 
and the rigid-body assumption. In these methods, efforts 
have been directed towards improvement of spatial con-
formational search by introduction of new minimization 
techniques. Simulated annealing by using Monte Carlo 
simulations facilitated the use of constraint-driven docking.82 
One of the most important advances was the use of Fourier 
transformation techniques to rapidly evaluate all possible 
translations between the molecules in a given orientation 
in order to find the best geometry matching6 This method 
actually constitutes the basis of some of the most popular 
rigid-body docking approaches nowadays (eg, FTDOCK83 
or ZDOCK).84,85 Other successful geometric-based docking 
methods are Hex86 and MolFit.6
In general, geometry-based rigid-body docking methods 
were able to find and score properly the correct solution 
when using the 3-D coordinates of the complexed subunits 
during simulations.6,8,87–90 However, when these methods 
were tested on real cases, using the 3-D coordinates of the 
uncomplexed subunits, the correct solution was often not 
properly discriminated from the false positives, or even was 
not found at all.8,88–90 Clearly, the geometry criterion was valid 
to rebuild a complex after separation of its bound subunits, 
given the additional induced shape complementarity of their 
Figure 2 Shape complementarity at the interface of a protease-inhibitor complex 
(chymotrypsin/APPi; PDB code 1ca0).
Abbreviation: PDB, Protein Data Bank.Advances and Applications in Bioinformatics and Chemistry 2009:2 106
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surfaces, but it was not able to correctly dock the unbound 
subunits, because their interacting surfaces are not always 
complementary enough. Thus, in order to model the induced 
fit that occur upon protein–protein association, it was neces-
sary to overcome the rigid-body assumption, and to include 
in the scoring function other binding determinants than pure 
geometrical complementarity.
Protein docking as a global energy minimization 
problem
During formation of a protein–protein complex, the interacting 
interfaces of the approaching subunits fit each other to reach 
the native bound conformation. Since protein complexes are, 
in general, thermodynamically stable systems, the native 
bound conformation should represent the global minimum 
of the free energy, and therefore the docking problem can 
be reduced to finding this global minimum. From this point 
of view, geometry-based docking methods considered that 
the interaction energy was proportional to the contact area. 
Whereas this geometry-based approach can account reason-
ably well for the van der Waals interactions, it is clearly insuf-
ficient to describe other contributions to the interaction energy. 
Thus, different docking methods were developed to include 
other binding determinants, such as hydrogen bonding,91 
electrostatic energy,92,93 solvation94 or hydrophobicity.95
At the same time, finding the global minimum of the free 
energy for a protein–protein association presented a confor-
mational search challenge. As the rigid-body approach was 
insufficient to simulate the induced conformational fit upon 
binding, docking methods started to include strategies to mimic 
molecular flexibility during the optimization (Bonvin reviewed 
all the diverse strategies developed to deal with molecular flex-
ibility upon binding during the docking process).10 The most 
practical strategy was the softening of the scoring function by 
imposing some limiting values to the steric energy terms, thus 
allowing some overlap of the interacting surfaces.83,96–100 This 
strategy overcame, to some extent, the difficulties stemming 
from the use of the unbound conformations of the interacting 
molecules. Explicit treatment of flexibility could lead to a more 
accurate description of the protein–protein complex formation 
phenomenon, but a full conformational search is currently 
impractical. However, since molecular association involves 
only small conformational changes in most of the known 
protein–protein complexes,63,101 computational requirements 
can be dramatically lowered by limiting conformational flex-
ibility to interface side chains.102–108
The first docking method that considered continuous flex-
ibility of interface side-chains during the global minimization 
process was based on internal coordinate mechanics 
(ICM).109–112 The ICM flexible docking procedure, success-
fully applied to the prediction of an antibody-lysozyme 
complex,113 was tested in a blind prediction contest.114 
Although the ICM pseudo-Brownian method115 with sub-
sequent global optimization116 of the interface side chain 
rotations lead to promising results, it was computationally 
too expensive to be tested on large databases of complexes. 
Therefore, an alternative two-step docking procedure (rigid 
body docking followed by ICM side-chain optimization) was 
proposed.9 The docking method used a fast soft interaction 
energy function pre-calculated on a grid,117 similar to the fast 
ligand docking procedures,118 which drastically increased 
the speed of the procedure.9 The scoring function used to 
evaluate the rigid-body docking poses was further optimized, 
for a better selection of docking solutions before the refine-
ment step.119 The scoring function, composed by Coulombic 
electrostatics and ASA-based desolvation energy with atomic 
solvation parameters optimized for protein–protein docking, 
was later implemented in a docking protocol called pyDock, 
which was able to score docking sets generated by different 
docking methods.11 Other docking and/or scoring schemes 
that are based on energy description are Haddock,120 ClusPro/
SmoothDock,107,121 RosettaDock108 and ATTRACT.122
Baker and colleagues improved side-chain modeling dur-
ing docking significantly using a rapid and efficient method 
for sampling off-rotamer side-chains conformations by tor-
sion space minimization. Their approach to include flexibility 
yielded better energetic discrimination between correct and 
incorrect docking models and a significant improvement 
in the quality of their predictions.123 Other approaches aim 
to include backbone flexibility by using conformational 
ensembles of the unbound subunits previously computed by 
Molecular Dynamics124,125 or by precalculating soft collective 
degrees of freedom by normal mode analysis (NMA) that are 
later used to include flexibility during docking.126 However, 
fully unrestricted molecular dynamics are too costly for 
routine application during docking. Nevertheless, there are 
important advances, as the use of steered molecular dynamics 
to give insights into the energy determinants and mechanism 
of TCR-pMHC association.127
Benchmarking protein–protein docking methods
To be used in practical applications, the protein–protein 
docking methods first have to be validated on a sufficiently 
large and diverse set of experimentally solved complex 
structures, ideally with individual subunit structures also 
experimentally determined. The problem is that there are Advances and Applications in Bioinformatics and Chemistry 2009:2 107
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not so many cases suitable for benchmarking. In one of the 
earliest benchmarking efforts, Norel and colleagues tested 
a rigid-body docking method on a set of complexes, starting 
from bound and unbound components. When the unbound 
subunits for both partners (in four different complexes) were 
used, the near-native solution had the lowest energy (eg, was 
identified as best docked) in only one case.8 FTDOCK dock-
ing method with refinement of binding side-chains was also 
benchmarked in a set of complexes (five cases when using 
unbound subunits). The near-native solution was ranked 
below 20 in all five cases, but it was predicted as the low-
est energy solution in only one.105 BiGGER rigid-body 
method was later applied to 11 protein–protein complexes 
using the unbound subunits. The near-native solution was 
found among the docked conformations in eight out of the 
11 cases, but was not ranked first in any of them.100 The ICM 
protein–protein docking9 was applied to a set of twenty-four 
protein–protein complexes (starting from the 3-D coordinates 
of bound and unbound subunits). When the unbound sub-
units were used, the near-native conformation was ranked 
below 20 in 85% of the complexes with no major backbone 
rearrangement upon binding (it was ranked 1 in 64% of the 
protease-inhibitor complexes). Recently, the laboratory of 
Weng has made an effort in providing suitable sets of cases 
for benchmarking of protein–protein docking methods.128–130 
Nowadays, it is almost standard to provide success rates on 
these benchmarks.11,108,131
In 2001, an international protein–protein docking experi-
ment called Critical Assessment of PRedicted Interactions 
(CAPRI; http://www.ebi.ac.uk/msd-srv/capri/capri.html) 
was launched, based on the CASP experiment model for 
single protein structural prediction. CAPRI is a blind test to 
evaluate the capacity of protein–protein docking algorithms 
to predict the binding-mode of two interacting proteins. This 
experiment allows direct comparison of different docking 
algorithms and permits also to follow the evolution of the 
performance of the most popular docking methods along 
time.132–135 Table 2 shows the results of all the CAPRI rounds 
that have been assessed so far, where the performance of the 
most active groups can be compared. In Figure 3 we can see 
three different examples of CAPRI results for the ICM and 
pyDock methods for targets 6, 14, and 25.
evaluate suitability for small-molecule 
binding (drugability)
Computational methods to analyze the small-molecule 
drugability of a target protein–protein interface focus on the 
existence of ‘hot-spots’ and/or small pockets. Although the 
overall chemical composition of protein interfaces does not 
significantly differ from the rest of the solvent-accessible 
surface,61–63 structural analysis and experimental studies 
on protein–protein complexes underline the existence of 
‘hot-spots’, eg, a few residues that confer most of the binding 
energy.136,137 These ‘hot-spots’ can be potential targets for 
small molecule drug discovery.138 Indeed, a specific inter-
action may be disrupted by targeting one or several of its 
hot spots. Consequently, low molecular weight compounds 
satisfying the requirements for orally deliverable drugs can 
be used to interfere with recognition sites in protein–protein 
interfaces that are usually above 800 Å2.139 Hot-spots can also 
be particularly helpful in difficult cases in which no small 
cavities are identified in flat protein–protein interfaces.
Experimental measurement of residue contributions to 
binding energy can be done by Alanine Scanning Muta-
genesis combined with biophysical methods but this is a 
quite costly way to identify hot-spots. Therefore efforts have 
focused on computational prediction of these residues, and 
a variety of approaches have been reported based on residue 
conservation,140,141 machine-learning algorithm from protein 
sequence alone,142 hydrogen bonding,143 complete binding 
energy evaluation144–146 or propensity calculation from rigid-
body docking.53 In Figure 4 we can see the high correlation 
between the hot-spot predictions from docking53 and the 
known experimental data for the IL4–IL4 receptor α chain.
The protein–protein interfaces most easily targeted with 
small molecule drugs typically contain a sufficiently deep 
surface pocket suitable for small molecule binding.147 Experi-
mental and computational prediction of binding pockets 
on the surface of proteins has been successfully applied to 
rational drug design,148–153 and thus they can be one of the first-
choice computational tools to characterize a protein–protein 
interface in search of potential pockets.
Discovery of inhibitors/promoters 
of PPI
Given the role of PPI in regulating the majority of biological 
functions, PPI inhibition has long been one of the major goals 
in drug design. Empirical discovery of small compounds 
that can disrupt PPI has been traditionally difficult,154 and 
structure-based design of PPI inhibitors is currently limited 
to only a few successful cases. However, recent develop-
ment of computational methods for protein–protein and 
protein-ligand docking is expected to facilitate the rational 
discovery of small compounds that can modify PPI. Several 
reviews of PPI modulation by small molecules have been 
published.155–157 Although the current review focuses on Advances and Applications in Bioinformatics and Chemistry 2009:2 108
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computational approaches, we will overview here several 
examples of experimental discovery of compounds that can 
modify PPI, and we will give later more extended information 
on rational design of new PPI inhibitors based on structural 
data and computer simulations.
Discovery of PPi agonists/antagonists: 
experimental approaches
Phage-display selection of peptides
Phage display has been used to probe hot-spots as well 
as to identify novel peptide agonist/antagonists of PPI.158 
For example, it has been used to select small peptides 
that can induce oligomerization in different cytokine 
receptors).157,159,160 Especially interesting was the case of the 
20 residue cyclic peptide EMP-1,161 which induced dimeriza-
tion of the EPO receptor. A small change in this sequence 
transformed its agonist character into antagonist.162 Cwirla 
and colleagues also identified small peptides that can induce 
receptor dimerization in thrombopoietin receptor (TPOR).163 
An interesting drug discovery platform that used phage 
peptide libraries and HTS of small molecules based on the 
selected peptides was reported.164 This strategy was applied 
to the discovery of agonist/antagonist peptides and small 
molecules in the insulin-like growth factor-1 (IGF-1)/IGF-1 
receptor system, and has been also used to identify a binding 
epitope and potential protein–protein interaction partners of a 
given protein, by searching in the sequence databases. In the 
case of the insulin receptor, both agonists and antagonists 
have been discovered using phage display. This technology 
even allowed a better understanding of the receptor molecular 
architecture with identification of critical regions required 
for its biological activity.165 Potent antagonists called “zeta” 
peptides of the high-affinity immunoglobulin E (IgE) receptor 
have also been identified and prevent histamine release 
from cultured cells. Moreover, these peptides that acts as 
competitive IgE inhibitors can be used for further design of 
IgE inhibitors.166
Discovery and optimization of natural ligands
Natural products didemnaketals A and B were used to 
synthesize simplified analogs that inhibited HIV protease 
homodimerization.167 Chalcone derivatives, with known 
anticancer properties, were recently described to inhibit 
interactions between the human oncoprotein MDM2 and p53 
tumor suppressor protein.168,169 Cyclodextrin dimers (CD) that 
disrupt PPI by targeting hydrophobic patches have been also 
reported.170 Interestingly, small molecules and peptides can 
also induce an unwanted stabilization of a protein–protein 
complex. This is the case of Brefeldin A, a small hydrophobic 
compound produced by toxic fungi that has dramatic effects 
on mammalian cells. It has been proposed that brefeldin 
A works as an uncompetitive inhibitor stabilizing a transient 
“dead-end” complex between Arf exchange factor and Sec7 
domain of Gea1, Gea2 and Sec7 proteins.171 On the other 
A B C
Figure 3 CAPri Target examples: A) and B) are two high-quality models found with iCM and submitted for the CAPri Targets 6 and 14 respectively, C) is a medium quality 
model found with pyDock submitted for the CAPri Target 25. Complexes are shown as surface and ribbon.   The correct position of the ligand is shown in yellow ribbon, the 
model is shown in navy blue ribbon.
Abbreviations: CAPri, Critical Assessment of Predicted interactions; iCM, internal coordinate mechanics.Advances and Applications in Bioinformatics and Chemistry 2009:2 110
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side, a large number of natural compounds have been known 
to target the tubulin-tubulin interaction to stop cancer cells 
division, and some new molecules are currently used in 
clinical trial for cancer therapy.172
High-throughput screening of small molecules
High-throughput screening (HTS) methods have been used 
to discover small compounds capable of inhibiting PPI, 
especially when no structural information is available about 
the target proteins.173 In general, HTS is less successful 
in identifying PPI inhibitors than in identifying any other 
type of inhibitor: PPI are extended over a big interface 
(average binding energy per unit area: 9 cal/mol⋅Å2)154 
and are difficult to target with a small site-specific drug 
(average binding energy per unit area: 31 cal/mol⋅Å2). 
Tian and colleagues used a high-throughput, cell-based 
screen to detect small compounds that activated the murine 
granulocyte-colony-stimulating factor (G-CSF) receptor.174 
They found a small molecule (SB 247464;Figure 5a) that 
replaced the natural protein ligand G-CSF in its role of 
inducing oligomerization of G-CSF receptor chains, thus 
triggering the corresponding signal transduction pathways. 
Later, it was shown that SB 247464 could dimerize the 
G-CSF receptor in a different manner than G-CSF, through 
a Zinc mediated interaction. It also appeared that SB 247464 
and G-CSF bound to different sites on the receptor, given 
that the small compound was unable to compete with G-CSF 
receptor natural ligand to initiate the dimerization.175 This 
constituted one of the first examples of a synthetic small 
molecule capable of dimerizing cell surface receptors.
Similarly, Kimura and colleagues screened many com-
pounds capable of inhibiting the binding of thrombopoietin 
(TPO) to the cell surface receptor c-Mpl, necessary for 
triggering megakaryopoiesis and platelet production cascades 
after receptor oligomerization. They found two small 
inhibitor compounds, TM4 and TM41 (Figure 5b), which 
were able to replace the natural TPO in its role of inducing 
c-Mpl oligomerization.176
HTS techniques have also been used to find a molecule 
that inhibited interaction between EPO and EPO receptor 
(Figure 5c). A multimeric form of this molecule was 
also synthesized and shown to induce dimerization in the 
EPO receptor, thus mimicking the physiological role of 
EPO.177,178 A cell-based screening assay was also used to 
select a molecule (L-783,281) that activated insulin receptor 
(Figure 5d). The mechanism proposed was that L-783,281 
bound the tyrosine kinase domain of the insulin receptor, 
altering its conformation and leading to its activation.179
Combinatorial piperazinone libraries have been used 
to find compounds that disrupt the interaction between 
the transcription factor LEF-1 and the protein β-catenin, 
which accumulates in a majority of colorectal tumors.180 
The complex formed between the Tcf4 transcription factor 
and the β-catenin, also involved in colorectal tumors, has 
been investigated by screening several thousand of natural 
compounds, among which six inhibitors in the low micro-
molar range were found.181 A combinatorial chemical library 
based on a pyrimidineimidazole core has been designed to 
find inhibitors of the inducible nitric oxide synthase (iNOS). 
This enzyme that generates NO from l-arginine is involved 
A
B
C
Figure 4 Normalized interface propensity (NiP) calculation from rigid-body docking 
for the prediction of hot-spots on the complex between the iL-4 and its iL4 receptor 
α chain (complex PDB code 1iar). A) The iL-4 receptor α chain is represented as grey 
ribbon, and the dots represent the center of coordinates of each of the 12000 rigid-body 
docking solutions poses colored according to the pyDock scoring function on a 
scale from red to blue: lowest energy values are shown in red. B) The iL-4 receptor 
α chain surface is colored according to the NiP value of each residue obtained from 
the 100 lowest-energy docking solutions.   The predicted hot-spots corresponding to 
the highest NiP values (cutoff  0.4) are shown in red. C) The iL-4 receptor α chain 
surface is colored according to the available experimental data. The residues shown in 
red are the ones experimentally known as hot-spot (ie, they contribute more than 1 kcal.
mol-1 to the binding energy).   The residues shown in blue are experimentally known as 
nonhot-spot, and the residues in white have no available experimental data.
Abbreviations: iL, interleukin; PDB, Protein Data Bank.Advances and Applications in Bioinformatics and Chemistry 2009:2 111
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in tissue damage during inflammation and is fully active as a 
dimer. By screening, Devlin and colleagues found a class of 
potent, selective and cell permeable iNOS inhibitors capable 
of preventing its dimerization.182,183
The oncoprotein c-Myc, over expressed in many human 
tumors (lung, colon, Burkitt’s lymphoma), requires binding 
to its activation partner Max in order to interact with DNA 
and achieve its transcription factor function. Because of 
its potential therapeutic applications, this interaction was 
studied by HTS and allowed the discovery of two potent 
and selective dimerization inhibitors: Mycro1 and Micro2, 
both in the low micromolar range.184 The complex formed 
between TNF-alpha and its receptor TNFRc1 were known 
to be inhibited by antibodies and soluble receptors, but 
no potent small molecule was reported until Muckelbauer 
and colleagues performed screening on this system and 
discovered two inhibiting small-molecule compounds act-
ing through covalent modification of the receptor via a 
photochemical reaction.185 HTS has also been used to discover 
two classes of competitive antagonists for the interaction 
B7.1/CD28, involved into the T-cell response augmentation, 
with potential therapeutic applications in immunotherapy after 
transplantation or autoimmune diseases.186 More recently, 
a Rac activation-specific inhibitor of the Rac1-GEF inter-
action that could be useful for therapeutic targeting at Rac 
deregulation has also been found in this way.187
Fragment-based lead discovery
Fragment assembly is a recent approach developed to help find-
ing or optimizing leads during the drug discovery process. A set 
of small fragments are screened against the protein of interest 
and the binders are then combined to form small-molecule 
compounds, which significantly increases the search process 
efficiency. Indeed, the chances of finding a hit are higher than 
in conventional HTS.188 Hajduk and Greer analyzed the impact 
of fragment-based methods in drug design over the last decade, 
H2N
N
N
N
H
O
R
R =
R =
OH
NH
N
H
N
H
N
H
N
N
N
N
N
N
H
N
HN
HN
O
O
O
NH
H
N
OH
O
H
O
OMe
HN
NH2
Cl
TM4
TM41
A B
D C
Figure 5 A) Molecule SB 247464; B) Molecules TM4 and TM41; C) inhibitor of ePO-ePOr interaction; D) Molecule L-783, 281.Advances and Applications in Bioinformatics and Chemistry 2009:2 112
Grosdidier et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
showing a list of all the targets studied through fragment-based 
approach that lead to potent inhibitors discovery.189 For example, 
a potent inhibitor of the anti apoptotic Bcl-2 family proteins 
(Blc-2, Bcl-XL and Bcl-w) was discovered using NMR-based 
screening of small fragments combined with structure-based 
drug design. The molecule, called ABT-737 showed a strong 
capacity to reduce regression of solid tumors in mice.190 
Tethering is a fragment-based method relying on the reversible 
formation of a disulfide bridge between the target protein and 
the fragment. In this way, the search region is controlled by 
the introduction, by site-directed mutagenesis, of a cysteine 
residue near the site of interest of the target protein, which 
in addition facilitates the computational analysis of potential 
binding modes.191 With this approach, a known inhibitor (in the 
millimolar affinity range) of the interaction between IL-2 and its 
receptor got its affinity significantly increased. The X-ray struc-
ture of the previously known IL-2/inhibitor complex revealed 
an adaptive IL-2 interface, in which a small molecule binding 
site was created. The application of the tethering approach 
resulted in a clear improvement of the original molecule to the 
nanomolar affinity range.192,193
rational design of PPi inhibitors: 
computational approaches
In principle, the problem of PPI inhibition seems to be just 
a particular case of the broader drug design field, but a 
deeper analysis shows intrinsic characteristics that make it 
a distinct field. While drug design, in general, is focused on 
the discovery of small compounds that can bind into natural 
ligand-binding pockets or active centers of proteins of thera-
peutic interest,194 inhibition of PPI requires identification of 
small compounds capable of disrupting a large and highly 
complementary interaction surface between two proteins 
(Figure 6). The absence of well defined, deep pockets in 
protein–protein interfaces, and the large number of inter-
molecular contacts arising from their high geometrical and 
chemical complementarity makes the problem especially 
difficult. Nevertheless, several methods for rational design of 
PPI inhibitors have been recently applied to particular cases 
with some success. The constant increase in computational 
power and the development of new efficient and accurate 
computer tools for drug design are starting to yield promising 
results in this very challenging area.
Mimicking protein–protein interfaces:  
from peptides to small molecules
Antibodies capable of blocking or enhancing PPI have 
been reported, for example a monoclonal antibody that can 
induce homodimerization of erythropoietin receptor and 
triggers cell proliferation cascades,195 or a monoclonal anti-
body that may block critical PPI of HIV-1 integrase.196 The 
use of antibodies in cancer therapy is highly promising.197 
A B
Figure 6 An example of a protein-small molecule interface A: complex trypsin/rPr128515 inhibitor (PDB 1f0u) compared to a protein–protein interface B: complex ePO 
receptor/ePO (PDB 1eer).   The protein-small molecule interface A), with fewer inter-atomic contacts, is noticeably smaller and deeper than the shallow, large protein–protein 
interface B). The molecules are shown in the same scale.
Abbreviation: PDB, Protein Data Bank.Advances and Applications in Bioinformatics and Chemistry 2009:2 113
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However, clinical use of antibodies presents in practice 
numerous problems (high cost for large-scale production, 
drug delivery, immunoreactivity, etc.).198 Fortunately, there 
are some reported examples of design of small molecule 
inhibitors that mimic an antibody binding function.199,200 
Based on this strategy, Chrunyk and colleagues proposed to 
design small compounds to mimic the binding of antibodies 
that can act as blocking agents of PPI.201 They selected a 
monoclonal antibody to block interaction between proteins 
IL-1β and IL-1R and they found that a simpler single chain 
antibody retained the same blocking capacity, leaving the 
door open for future design of PPI inhibitors. Similarly, 
a calyx[4]arene scaffold with pendant cyclic peptide units 
was designed as a mimetic of antibody Fab fragments, and 
was shown to bind cytochrome c in the same region of the 
protein as its natural protein partners (cytochrome oxidase, 
cytochrome c peroxidase).202
Structure-based design of peptides that mimic structural 
elements of a protein–protein interface203,205 has been widely 
applied for the inhibition of PPI.155,206,207 Some examples of 
the so-called “interface peptide” strategy include: peptide 
inhibitors of different adhesive proteins such as α−actinin 
and vinculin;208,209 short peptides that inhibit homodimeriza-
tion of HIV-1 protease;210,211 a stabilized helicoidal peptide 
that inhibits a domain-domain interaction between the 
N-terminal and C-terminal domains of the HIV-1 enve-
lope glycoprotein gp41, disabling thus membrane fusion 
between the virus and target cells;212 synthetic peptides that 
inhibit homo-dimerization of thymidylate synthase (TS);213 
a β-sheet peptide that inhibits dimerization of the small E47 
transcription factor;214 a synthetic cyclic heptapeptide that 
inhibits interaction between CD4 and major histocompat-
ibility complex (MHC) class II proteins;215,216 synthetic 
peptides that block interaction between CD8 and MHC class I 
proteins;217 synthetic peptides that inhibit dimerization of the 
HIV reverse transcriptase;218–220 inhibition of HIV-1 protease 
homodimerization by a small tethered peptide;221 inhibition 
of the herpes simplex virus ribonucleotide reductase dimer-
ization by a small hexapeptide resulting in a stronger effect 
on replication than the Acyclovir;222 and peptides targeting 
SH3-mediated PPI.223 Ferrer and colleagues used a combina-
torial chemical library to find elements that, when covalently 
attached to a peptide derived from the outer layer α-helix, 
could inhibit gp-41-mediated HIV-1 cell entry.224 Based on 
the X-ray structure of the inhibitor in complex with the HIV-1 
gp41 trimeric core,225 they showed that blocking a small cavity 
was sufficient to inhibit the interaction between the core 
coiled-coil and the outer-layer α-helix of gp41. However, the 
small molecule alone had no inhibitory activity, although it 
increased the potency of the 30-mer mimetic peptide.
The discovery of peptide, peptidomimetic and small 
molecule inhibitors of the association between integrin 
α4β1 (VLA-4) and the endothelial surface protein vascular 
cell adhesion molecule (VCAM) was reported.226–228 
A review of structure-based design of phosphopeptides 
and small molecule inhibitors of Grb2-SH2 mediated PPI 
has been published.229 A peptide sequestering the anti-
apoptotic protein Bcl-2 has been optimized to increase its 
“mimicking” capability with respect to the BH3 domain of 
BID (a pro-apoptotic BH3-only protein) by hydrocarbon 
stapling. The resulting BH3 domain alpha-helix is more rigid, 
protease-resistant, cell permeable and binds with increased 
affinity to Bcl-2. This inhibitor suppresses the growth of 
human leukemia cells in vitro, and it prolongs the survival 
of leukemic mice in vivo.230 Furet and colleagues applied a 
structure-based approach to improve 1700-fold the binding 
affinity towards hdm2 of their initial peptide derived from 
the N-terminal domain of p53. They discovered potent 
antagonists of the p53-hdm2 interaction, which constitutes 
an attractive approach for cancer therapy.231 Several “two 
turns” structural mimics of the myosin light chain kinase 
present functional homology in its high affinity binding to 
calmodulin, and are able to inhibit the calmodulin activation 
of PDE enzyme in the nanomolar range.232
Although design of peptide molecules that mimic 
protein–protein interfaces or antibody binding is an interesting 
approach, the ultimate goal is the design of small nonpeptidic 
PPI inhibitors (generally with MW  500), more desir-
able for therapeutic use than peptides or peptidomimetics. 
Tilley and colleagues designed a series of acylphenylalanine 
derivatives intended to mimic the proposed binding region of 
interleukin-2 (IL-2) to the α receptor subunit (IL-2Rα), based 
on a combination of structural information of IL-2 (by X-ray 
and NMR data) and site-directed mutagenesis. Structure-
activity studies led to a small compound with an IC50 µM.233 
Similarly, Sarabu and colleagues designed a series of small 
molecule antagonists for the interaction between interleukin-1 
alpha protein (IL-1α) and the Type I receptor, with potential 
interest to treat inflammation related diseases.234 The design 
was based on the 3-D structure of the proposed binding 
epitope for IL-1β (derived from the X-ray structures of IL-1 
ligands and site-directed mutagenesis data).
Nonpeptidic inhibitors of the interaction between 
fibrinogen and GPIIb-IIIa integrin, association that is essen-
tial for platelet aggregation, have been designed based on 
the tripeptide sequence Arg-Gly-Asp (RGD).235,236 Several Advances and Applications in Bioinformatics and Chemistry 2009:2 114
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of these molecules (xemilofiban, orbofiban, sibrafiban, and 
lotrafiban; Figure 7) have progressed until phase III clinical 
trials but unfortunately they did not reach the market due to 
both a lack of efficacy237 and safety concerns. Other nonpep-
tidic RGD mimics have been designed based on spirocyclic 
structures.238,239
Based on the structure of the complex between the B 
domain (Fb) of Staphylococcus aureus protein A (SpA) and 
the Fc fragment of IgG (Figure 8a),240 Li and colleagues used 
computer-aided molecular modeling to design a molecule 
mimetic for protein A (Figure 8b) that is an effective competi-
tive inhibitor for its interaction with IgG (Figure 8c).241
Another interesting strategy for PPI inhibition is the use of 
transition metal complexes to target distinctive patterns of 
histidine residues on the surface of a protein.242 A review 
of rational design of PPI inhibitors involving the TNF family 
cytokines has been published.243 A different area of therapeutic 
interest involving PPI is the formation of amyloid fibrils. 
Klabunde and colleagues discovered small compounds that 
can inhibit transthyretin (TTR) fibril formation by stabilizing 
the native tetrameric conformation of TTR.244 They used a 
structure-based drug design approach based on the crystal 
structures of TTR complexed with known amyloid fibril 
inhibitors. Their work represents a good example of modulating 
PPI by enhancing stability of the complexed conformations 
avoiding unbound conformations that lead to disease.
Protein interfaces can be artificially re-engineered. 
A particularly difficult task is to break strong PPI in which 
two monomers are interlocked through extensive interactions 
and side-chain mutations are insufficient. Borchert and 
colleagues re-engineered the backbone of loop3 at the inter-
face between two triose-phosphate isomerase monomers, 
which led to predicted monomeric structures.245,246 Engineered 
protein–protein interfaces, artificially disrupted after the intro-
duction of cavities by using alanine-scanning mutagenesis, 
can be restored with small molecules bound to the cavity, 
thus generating artificial small molecule switches for PPI.247 
Although rational design of the protein–protein interfaces 
themselves has limited therapeutic interest, it could be useful 
to understand the physicochemical basis of PPI modulation, 
and also to generate manipulated organisms in biotechnology 
that functionally respond to specific molecules.
Computer-aided design: virtual screening 
and docking simulations
Computational simulations is increasingly facilitating 
rational design of small molecules that can inhibit or stimu-
late the biological activity of specific proteins, mostly by 
targeting a clearly defined binding pocket.194,248 However, 
so far very few inhibitors of PPI have been designed using 
computer simulations (see recent reviews focused on virtual 
screening for the identification of inhibitors of PPI).249–251
Computational approaches have been successfully 
applied to optimize peptidic ligands in several systems. 
Zeng and colleagues used a combinatorial algorithm252 
based on the MCSS approach149 for the optimization of 
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peptides that inhibit the association between Ras and Raf, 
proteins involved in signal transduction pathways and in 
many oncogenic events.253 Furet and colleagues254–256 opti-
mized the inhibition properties of the phospho-tripeptide 
pTyr-Ile-Asn by molecular modeling and found a derivative 
capable of blocking the interaction between the activated 
tyrosine kinase growth factor receptors (TKGFR) and the 
SH2 domain of Grb2 (see a review of SH2 domain and drug 
discovery).257 Proline-rich peptides targeting SH3 domains 
were computationally optimized using the programs GRID117 
and LUDI,258 obtaining an increment of 100-fold in affinity 
and 1000-fold in selectivity.
HN
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Figure 8 A) Structure of the complex (PDB: 1fc2) between the Staphylococcus aureus Protein A Fb domain (solid surface) and the igG Fc fragment (red); Side-chains of binding 
residues Phe132 and Tyr133 of Protein A are shown in yellow; B) Small molecule competitive inhibitor ApA; C) Model of the interaction between igG (solid surface) and 
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Fewer computational methods have been developed for 
rational design of small nonpeptidic compounds to inhibit 
PPI. Li and colleagues applied computer screening to select 
small nonpeptidic organic molecules that can inhibit interac-
tion between CD4 and MHC class II proteins.147 Based on the 
X-ray structure of the human CD4 D1 domain,259 and using a 
combination of theoretical prediction and synthetic peptide 
experiments, the authors identified a surface pocket potentially 
involved in functional binding to MHC class II (Figure 9a). 
The identification of such a surface pocket was critical for 
the success of the strategy. The authors used the computer 
program DOCK3.5260 to screen the available chemicals 
directory (ACD) (Molecular Design Limited, San Leandro, 
CA, USA), that included around 150,000 commercially 
available small organic compounds, in search for possible 
ligands to that particular pocket. They finally selected four 
compounds with significant inhibitory activity (45%–75% at 
100 µM) for the CD4-MHC class II interaction (Figure 9b).
A novel class of low molecular weight hydantoins, 
which inhibits the interaction between the lymphocyte 
function-associated antigen-1 (LFA-1) and the intercellular 
adhesion molecule (ICAM-1) by allosteric regulation,262 
represented an alternative example of PPI regulation. 
Based on an integrated immunochemical, chemical, and 
molecular modeling approach, the following allosteric 
inhibition mechanism was proposed: the hydantoins bind 
to LFA-1 and drive the equilibrium between active and 
inactive states of LFA-1 towards the conformation that is 
unable to interact with ICAM-1.263 Bushweller and colleagues 
found four new inhibitors that effectively blocked the 
interaction between Runx1 and CBFβ with low micromolar 
affinity, amongst 35 potential candidates selected by virtual 
screening. An NMR spectroscopy screening study showed 
later that none of these compounds were directly bound to 
the protein–protein interface, which suggested the existence 
of allosteric effects in the inhibition.264
Virtual screening has been used to identify 13 nonpep-
tide drug-like inhibitors targeting the p56Lck SH2-domain 
from an initial screening of 25,000 compounds.265 Amongst 
the 13 inhibitors, two were identified as potential lead 
compounds for further development.266 In another example, 
virtual screening of 640,000 compounds was performed with 
DOCK4.0.1 in order to target the interaction between S100B 
and p53, which lead to the discovery of seven inhibitors 
in the micromolar range. Five of these compounds inhib-
ited growth of primary malignant melanoma cells and are 
currently being optimized to find higher affinity inhibitors 
for potential applications in cancer therapy.267 The extra-
cellular kinases ERK1/2, which play an important role in a 
signaling pathway involved in proliferation, are believed to 
be interesting targets to arrest cell proliferation in cancer. 
Only two proteins are known to turn on ERK1/2 kinases, 
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which then are able to phosphorylate dozens of proteins 
in vitro. Shapiro and colleagues applied a virtual screening 
approach to specifically target the ERK phosphorylation 
of two substrates: RSK-1 and ELK-1. The discovered 
compounds were able to inhibit the proliferation of several 
cancer cell lines in vitro.268 A recent study combined virtual 
fragment analysis and selection by molecular docking (using 
five different scoring functions) with an NMR-screening 
experiment called fluorine chemical shift anisotropy 
and exchange for screening (FAXS). The approach 
permitted the identification of a molecule displaying 
a strongly favorable binding enthalpy as tested by isothermal 
titration calorimetry (ITC), which suggested an enhanced 
selectivity for the v-src tyrosine kinase SH2 domain. 
Finally, computational modelling of the interaction nicely helped 
to explain the high binding enthalpy of this compound.269
Drug design and regulation of PPI: 
clinical applications
Very few of the designed molecule inhibitors of PPI have 
been clinically tested. One example is a synthetic cyclic 
heptapeptide that inhibits interaction between CD4 and MHC 
class II proteins and that has been approved by the United 
States Food and Drug Administration for a phase I clinical 
trial in graft-versus-host disease (GVHD) prophylaxis in bone 
marrow transplant patients.215,216 Another example is a new 
thrombopoetic growth factor, eltrombopag (or SB-497115), 
which is actually in phase III clinical trials as an oral and 
nonpeptide thrombopoetin receptor agonist for the treatment 
of idiopathic thrombocytopenic purpura.270–272 Genetech 
(San Francisco, CA, USA) is also developing pertussis toxin 
(IAP) antagonists,273 a novel class of cancer therapeutics,274 
and one of the molecules is now in phase I clinical trials.275
Numerous factors can affect the output of an interaction 
network in a living organism. Some studies suggest than small 
changes in effector concentration can be more significant 
than absence or presence of a particular component, and 
the response can depend highly upon the biology of the 
system.159,276 The complexity of the response of the interac-
tion networks in living organisms upon small changes in the 
environment makes the possibility of controlling signaling 
pathways with small compounds extremely challenging, 
although in the near future it will undoubtedly become one 
of the hottest areas in medicinal chemistry.
Conclusions
Targeting protein–protein interfaces with a small molecule 
is much more difficult than targeting a natural ligand pocket 
with another compound, due to the large and distributed set 
of interactions, the frequent lack of deep pockets, and the 
induced fit of the protein interfaces. A careful analysis of a 
protein–protein interface in search of putative small-molecule 
binding pockets, together with extensive computational 
protein-ligand docking simulations (virtual screening), 
will help to improve the rational design of PPI inhibitors. 
Computational prediction of “hot-spots” (for protein and 
ligand binding) at the surface of proteins can help to focus 
virtual screening or protein-ligand docking studies onto 
specific areas of a protein surface, and thus prioritize a 
large number of putative protein–protein interaction targets 
according to their potential to lead to a small molecule 
modulator. Finally, new improved protein–protein docking 
methods will be essential to predict the protein interfaces, 
and evaluate the PPI inhibition or oligomerization modula-
tion capability of the selected compounds.
A combination of experimental and computational 
techniques, together with a deep knowledge of the determi-
nants of protein–protein and protein-ligand interactions is 
necessary for the successful design of small compounds that 
can specifically modify PPI of therapeutic interest. The field 
is at its very early stage, but it constitutes a highly promising 
area of therapeutic proteomics.
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